Pinnacle Medicines Secures $89 Million in Series B Funding

Pinnacle Medicines Secures $89 Million in Series B Funding

Pinnacle Medicines, a biotechnology firm based in Doylestown, Pennsylvania, has successfully closed an $89 million Series B funding round as of March 25, 2026. The round was co-led by LAV and Foresite Capital, with additional participation from Quan Capital, Hankang Capital, RA Capital Management, Logos Capital, and existing investors including OrbiMed.

Company Overview

Pinnacle Medicines is at the forefront of developing oral peptide therapeutics using a proprietary platform that combines artificial intelligence, physics-based molecular simulations, and advanced peptide chemistry. The company's innovative approach aims to offer biologic-level efficacy through the convenience of oral dosing, targeting pathways in immunology and cardiometabolic diseases.

Founders and Executives

The company was co-founded by Chengzao Sun, who serves as the Chief Scientific Officer, and Sandeep Somani, the Chief Technology Officer. Both founders have been instrumental in driving the company's vision of creating a new generation of oral peptide therapeutics.

Strategic Use of Funds

The newly acquired funding will be utilized to advance Pinnacle's pipeline of oral peptide programs. These programs focus on developing first- and best-in-class treatments aimed at validated pathways in critical therapeutic areas. The investment will support the enhancement of Pinnacle's discovery platform and the acceleration of its research and development initiatives.

Investor Insights

The participation of both new and existing investors highlights the confidence in Pinnacle Medicines' innovative approach and potential impact in the biotechnology sector. Co-lead investors LAV and Foresite Capital are joined by Quan Capital, Hankang Capital, RA Capital Management, Logos Capital, and OrbiMed in backing the company's continued growth.

Conclusion

With this significant funding boost, Pinnacle Medicines is well-positioned to further its mission of delivering convenient and effective oral peptide therapeutics. The company's unique platform and strategic focus on critical health areas make it a notable player in the biotech industry.